Effectiveness of SPECT/CT Imaging for Sentinel Node Biopsy Staging of Primary Cutaneous Melanoma and Patient Outcomes.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
08
07
2021
accepted:
31
08
2021
pubmed:
28
10
2021
medline:
6
1
2022
entrez:
27
10
2021
Statut:
ppublish
Résumé
Coregistered SPECT/CT can improve accuracy of sentinel node biopsy (SNB) for staging melanoma. This benefit has implications for pathology services and surgical practice with increased diagnostic and surgical workload. The purpose of this study was to investigate the effectiveness of SPECT/CT imaging. SNB data were collected over a 10-year period. Preoperative SLN mapping was performed by using planar lymphoscintigraphy (LSG) for all patients (n = 1522) and after October 2015, patients underwent a second co-registered SPECT/CT scan (n = 559). The patients were stratified according to the imaging protocol. The number of nodes and nodal basins were assessed. The reasons for cancellation also were assessed. A total of 95% (1446/1522) of patients underwent a successful SNB procedure. Significantly more sentinel nodes were identified by the SPECT/CT protocol (3 vs. 2; p < 0.0001). More patients were cancelled in the SPECT/CT cohort (9.3% vs. 2.5%; p < 0.0001). Head & neck, lower limb, and AJCC IB primaries were significantly less likely to proceed to SNB. SPECT/CT identified significantly more positive SNBs (20.9% vs. 16.5%; p = 0.038). SPECT/CT imaging was associated with improved disease-free (hazard ratio [HR] = 0.74; 95% confidence interval [CI]: 0.54-1.0); p = 0.048) and disease-specific survival (HR = 0.48; 95% CI: 0.3-0.78; p = 0.003). Patients who did not proceed to SNB had a significantly increased nodal relapse rate (23.5% vs. 6.8%; HR = 3.4; 95% CI: 1.9-6.2; p < 0.0001) compared with those who underwent SNB. This large cohort study confirms the increased accuracy of SPECT/CT for identifying SLN metastases, which would appear to have a significant therapeutic benefit, although an increased risk of cancellation of the SNB procedure on the day of surgery.
Identifiants
pubmed: 34704182
doi: 10.1245/s10434-021-10911-4
pii: 10.1245/s10434-021-10911-4
pmc: PMC8724187
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
767-775Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. The Author(s).
Références
Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.
doi: 10.1001/archsurg.1992.01420040034005
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual: Melanoma Staging: AJCC 8th Edition. CA Cancer J Clin. 2017;67:472–92.
Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American society of clinical oncology and society of surgical oncology clinical practice guideline update. J Clin Oncol. 2018;36:399–413.
doi: 10.1200/JCO.2017.75.7724
Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242:302–11; discussion 311–3.
Karim RZ, Scolyer RA, Li W, et al. False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology. Ann Surg. 2008;247:1003–10.
doi: 10.1097/SLA.0b013e3181724f5e
Uren RF. SPECT/CT Lymphoscintigraphy to locate the sentinel lymph node in patients with melanoma. Ann Surg Oncol. 2009;16:1459–60.
doi: 10.1245/s10434-009-0463-z
Klode J, Poeppel T, Boy C, et al. Advantages of preoperative hybrid SPECT/CT in detection of sentinel lymph nodes in cutaneous head and neck malignancies. J Eur Acad Dermatol Venereol. 2011;25:1213–21.
doi: 10.1111/j.1468-3083.2010.03954.x
Doepker MP, Yamamoto M, Applebaum MA, et al. Comparison of Single-Photon Emission Computed Tomography-Computed Tomography (SPECT/CT) and Conventional Planar Lymphoscintigraphy for Sentinel Node Localization in Patients with Cutaneous Malignancies. Ann Surg Oncol. 2017;24:355–61.
doi: 10.1245/s10434-016-5590-8
Trinh BB, Chapman BC, Gleisner A, et al. SPECT/CT adds distinct lymph node basins and influences radiologic findings and surgical approach for sentinel lymph node biopsy in head and neck melanoma. Ann Surg Oncol. 2018;25:1716–22.
doi: 10.1245/s10434-017-6298-0
Veenstra HJ, Vermeeren L, Olmos RAV, et al. The additional value of lymphatic mapping with routine SPECT/CT in unselected patients with clinically localized melanoma. Ann Surg Oncol. 2012;19:1018–23.
doi: 10.1245/s10434-011-2031-6
van der Ploeg IMC, Valdés Olmos RA, Nieweg OE, et al. The additional value of SPECT/CT in lymphatic mapping in breast cancer and melanoma. J Nucl Med. 2007;48:1756–60.
doi: 10.2967/jnumed.107.043372
Peach H, Board R, Cook M, et al. Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: a UK consensus statement. J Plast Reconstr Aesthet Surg. 2020;73:36–42.
doi: 10.1016/j.bjps.2019.06.020
McMasters KM, Noyes RD, Reintgen DS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004;86:212–23.
doi: 10.1002/jso.20084
Hudak KA, Hudak KE, Dzwierzynski WW. Sentinel lymph node biopsy for melanoma: is there a correlation of preoperative lymphatic mapping with sentinel lymph nodes harvested? Ann Plast Surg. 2015;74:462–6.
doi: 10.1097/SAP.0b013e3182a1e544
Brody T. Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines. Elsevier Science; 2016.
Moncrieff MD, O’Leary FM, Beadsmoore CJ, et al. Effect of delay between nuclear medicine scanning and sentinel node biopsy on outcome in patients with cutaneous melanoma. Br J Surg. 2020;107:669–76.
doi: 10.1002/bjs.11460
Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.
doi: 10.1056/NEJMoa1310460
Melanoma: Cutaneous. NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf . 2021. Accessed 10 Apr 2021.
Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377:1824–35.
doi: 10.1056/NEJMoa1709030
Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant Dabrafenib plus Trametinib in Stage III melanoma. N Engl J Med. 2020;383:1139–48.
doi: 10.1056/NEJMoa2005493
Bluemel C, Herrmann K, Giammarile F, et al. EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma. Eur J Nucl Med Mol Imaging. 2015;42:1750–66.
doi: 10.1007/s00259-015-3135-1
Nielsen KR, Chakera AH, Hesse B, et al. The diagnostic value of adding dynamic scintigraphy to standard delayed planar imaging for sentinel node identification in melanoma patients. Eur J Nucl Med Mol Imaging. 2011;38:1999–2004.
doi: 10.1007/s00259-011-1880-3
Jimenez-Heffernan A, Ellmann A, Sado H, et al. Results of a prospective multicenter international atomic energy agency sentinel node trial on the value of SPECT/CT over planar imaging in various malignancies. J Nucl Med. 2015;56:1338–44.
doi: 10.2967/jnumed.114.153643
Quartuccio N, Garau LM, Arnone A, et al. Comparison of 99mTc-Labeled Colloid SPECT/CT and Planar Lymphoscintigraphy in Sentinel Lymph Node Detection in Patients with Melanoma: A Meta-Analysis. J Clin Med Res.;9 . Epub ahead of print June 2, 2020. DOI: https://doi.org/10.3390/jcm9061680 .
Stoffels I, Müller M, Geisel MH, et al. Cost-effectiveness of preoperative SPECT/CT combined with lymphoscintigraphy vs. lymphoscintigraphy for sentinel lymph node excision in patients with cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging. 2014;41:1723–31.
doi: 10.1007/s00259-014-2771-1
Reynolds HM, Walker CG, Dunbar PR, et al. Functional anatomy of the lymphatics draining the skin: a detailed statistical analysis. J Anat. 2010;216:344–55.
doi: 10.1111/j.1469-7580.2009.01183.x
Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the multicenter selective lymphadenectomy trial (I). Ann Surg Oncol. 2010;17:3324–9.
doi: 10.1245/s10434-010-1203-0
Melanoma skin cancer statistics. Cancer Research UK. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer . 2019. Accessed 30 Dec 2019.
Bello DM, Faries MB. The landmark series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes). Ann Surg Oncol. 2020;27:15–21.
doi: 10.1245/s10434-019-07830-w
Faries MB, Steen S, Ye X, et al. Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg. 2013;217:27–34; discussion 34–6.
Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211–22.
doi: 10.1056/NEJMoa1613210